<DOC>
	<DOCNO>NCT02948777</DOCNO>
	<brief_summary>Postprandial lipemia highly prevalent type 2 diabetes subject even normal fast triglyceride value . Humans mostly postprandial rather fast state therefore non-fasting triglyceride value reflect accurately continuous exposure arterial wall substantial cholesterol load . Evolocumab lower blood LDL-cholesterol . This study evaluate effect evolocumab postprandial lipid metabolism type 2 diabetes . All participant study receive evolocumab treatment .</brief_summary>
	<brief_title>Effects PCSK9 Inhibition Evolocumab Postprandial Lipid Metabolism Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female ( nonfertile use medically approve birth control method ) overweight/obese subject Type 2 Diabetes Mellitus treat lifestyle counsel stable metformin dose least three month age 1877 yr . body mass index 2540 kg/m2 triglycerides 1.54.5 mmol/L lowdensitylipoprotein cholesterol &gt; 1.8 ≤4.0 mmol/L ( Atorvastatin 20 mg/day ) glycohemoglobin : ≤9 % . Each patient attend prescreening visit ( week 5 ) eligibility criterion evaluate . If patient use another statin atorvastatin ( 20 mg ) screen visit use statin stop atorvastatin 20 mg initiate . If patient use statin , atorvastatin 20 mg initiate lipid value check 4 week inclusion/exclusion criterion assess . Type 1 diabetes apolipoprotein E2/2 phenotype alanine transaminase / aspartate transaminase &gt; 3× upper limit normal creatinine kinase &gt; 3× upper limit normal glomerular filtration rate &lt; 60 ml/min clinically significant thyroidstimulating hormone outside normal range body mass index &gt; 40 kg/m2 glycohemoglobin &gt; 9.0 % fast triglyceride &gt; 4.5 mmol/l total cholesterol &gt; 7.0 mmol/l positive urine serum pregnancy test untreated inadequately treat hypertension define blood pressure &gt; 160 mmHg systolic and/or &gt; 105 mmHg diastolic , use thiazide diuretic dose ≥25 mg/day subject stable dose atorvastatin ( 20 mg/ day randomization ) lipidlowering drug statin within 3 month diabetes medication except diet + metformin history/diagnosis diabetes nephropathy / retinopathy current smoking weekly alcohol use 24 dos men 16 woman history myocardial infarction , acute coronary syndrome coronary revascularization ( percutaneous coronary intervention coronary artery bypass graft ) within last 6 mo . plan revascularization ( eg coronary artery bypass grafting , percutaneous coronary intervention , carotid peripheral revascularization procedure ) within 3 month screen New York Heart Association class III/IV congestive heart failure persist despite treatment history hemorrhagic stroke hypersensitivity ( evolocumab ) excipients found drug product use estrogen therapy current use antithrombotic anticoagulant therapy know bleeding tendency would contraindication heparin test history cancer within past 5 year ( except adequately treat basal cell skin cancer , squamous cell skin cancer situ cervical cancer ) woman childbearing potential protected effective birth control method and/or willing tested pregnancy patient consider investigator subinvestigator inappropriate study reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>